CytoSorbents to Showcase Innovations at Jefferies Global Healthcare Conference

On June 4-5, 2025, CytoSorbents Corporation, a prominent player in the blood purification sector, will participate in the highly anticipated Jefferies Global Healthcare Conference in New York City. The event presents an invaluable opportunity for the company to engage with investors and demonstrate its cutting-edge technologies aimed at treating life-threatening conditions in intensive care and cardiac surgery.

Presentation Details

CytoSorbents management will present critical updates and innovations relating to their flagship product, CytoSorb®. The product, designed for use in various intensive care applications, utilizes biocompatible polymer beads to effectively remove toxic substances from blood, enhancing patient outcomes in critical scenarios. Investors can tune in to a live webcast of the presentation on June 5 at 9:20 AM ET, with a replay available for 90 days following the event.

The Role of CytoSorbents' Technologies

CytoSorbents specializes in blood purification systems that are instrumental in managing severe medical conditions. Their proprietary technology functions through a system of cartridges filled with highly porous beads that facilitate the removal of harmful substances in real-time, addressing challenges presented by critical illnesses such as sepsis, trauma, and cardiac conditions.

The breadth of applications for CytoSorb’s technology continues to expand, with particular focus on removing blood thinners like ticagrelor during cardiothoracic surgery to mitigate bleeding risks, as well as combating inflammatory agents during critical care treatment. This capacity to manage high-risk scenarios significantly enhances patient survival rates during challenging medical interventions.

Global Reach and Regulatory Developments

CytoSorb has proven its effectiveness across more than 70 countries, with over a quarter-million devices used to date. The product has also gained traction in European Union markets since its initial CE mark approval as the world's first cytokine adsorber. Following subsequent approvals for bilirubin and myoglobin removal in clinical settings, CytoSorb was granted FDA Emergency Use Authorization to aid critically ill COVID-19 patients.

In Canada and the U.S., CytoSorbents is advancing its DrugSorb™-ATR system, a potentially groundbreaking device aimed at reducing perioperative bleeding among patients using antithrombotic medications. While the device has received FDA Breakthrough Device Designation for its innovative approach, it awaits further regulatory approvals, incorporating ongoing dialogue with the FDA to refine its application.

Focus on the Future

Looking ahead, CytoSorbents is actively focusing on overcoming regulatory hurdles for DrugSorb-ATR through an appeal process that seeks to expedite a final decision in 2025. As the company navigates these complexities, its commitment to research and innovation remains steadfast. CytoSorbents also holds numerous other products in development, broadening the scope of their technologies in critical care contexts.

The Jefferies Global Healthcare Conference symbolizes not just an opportunity to foster investor relationships but also a platform to showcase CytoSorbents' significant contributions to modern medicine. As the company continues to lead advancements in blood purification, its presence at this event will undoubtedly shine a light on the wider implications of its innovations for healthcare today and in the future.

For more detailed information about the conference and its specific session links, please visit CytoSorbents and check the Events & Presentations section.

CytoSorbents remains dedicated to promising advancements in critical care through pioneering research and real-world applications that significantly enhance patient treatment options, embodying the essence of innovation in the healthcare sector.